TGRX-678 Phase I Oral Pharmacokinetic Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 24, 2024

Primary Completion Date

January 6, 2025

Study Completion Date

February 20, 2025

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

TGRX-678

All participants are given TGRX-678 orally at 240 mg

Trial Locations (1)

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors

collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY

NCT06697899 - TGRX-678 Phase I Oral Pharmacokinetic Study | Biotech Hunter | Biotech Hunter